ALBT - Avalon GloboCare Corp.

0.4038
-0.013   -3.269%

Share volume: 349,051
Last Updated: 04-23-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$0.42
-0.01
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 35%
Dept financing 43%
Liquidity 5%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-17.56%
1 Month
-29.88%
3 Months
-50.42%
6 Months
-81.81%
1 Year
-88.11%
2 Year
49.56%
Key data
Stock price
$0.40
P/E Ratio 
0.00
DAY RANGE
$0.38 - $0.42
EPS 
-$9.53
52 WEEK RANGE
$0.34 - $4.74
52 WEEK CHANGE
-$89.12
MARKET CAP 
9.685 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-30-2025
BETA 
-1.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,306,795
AVERAGE 30 VOLUME 
$2,587,818
Company detail
CEO: David K. Jin
Region: US
Website: http://www.avalon-globocare.com/
Employees: 5
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Avalon GloboCare Corp. owns and operates commercial real estate properties in the United States and the People's Republic of China. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia. It is also developing RNA-based FASH-CARTM cell therapy platform.

Recent news